Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25365883 | 0.81 | ABL1 (0.44) | BACE1ABL1ABCB1BCRRXRA | |
| SCHEMBL26784179 | 0.81 | ABL1 (0.49) | BACE1ABL1ABCB1BCRRXRA | |
| SCHEMBL18588973 | 0.80 | TSHR (0.46) | NOS1HTR7 | |
| SCHEMBL254443 | 0.79 | MAOB (0.55) | MAPT | |
| SCHEMBL21589900 | 0.76 | ABL1 (0.50) | ABL1ABCB1BCRRXRAPGR | |
| SCHEMBL4418405 | 0.75 | TAAR1 (0.54) | NOS3NOS1PARP1PARP2MAPT | |
| SCHEMBL24226868 | 0.75 | CYP11B1 (0.54) | NOS3NOS1BACE1 | |
| SCHEMBL21586168 | 0.75 | ABL1 (0.48) | BACE1ABL1ABCB1BCRRXRA | |
| SCHEMBL27852526 | 0.75 | ABL1 (0.44) | ABL1ABCB1BCRRXRAPGR | |
| SCHEMBL31207320 | 0.75 | ACP1 (0.47) | BACE1ABL1ABCB1BCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | NOS3 1216/4885NOS1 1185/4885BACE1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.